Clinical Trial Update: A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 dose-escalation study evaluating SGX942 for oral mucositis in patients with head and neck cancer; the trial has completed enrollment and results were po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Oral Mucositis

Drugs mentioned

• SGX942 (SGX942)

Snippet

Sponsor: Soligenix | Conditions: Oral Mucositis | Phase 2 | Status: COMPLETED | Results posted: 2017-07-31